Company Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging.
The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.
It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function.
It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries.
The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.
ChromaDex Corporation is headquartered in Los Angeles, California.
Country | United States |
IPO Date | Jun 25, 2008 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 106 |
CEO | Robert N. Fried |
Contact Details
Address: 10900 Wilshire Boulevard Los Angeles, California United States | |
Website | https://www.chromadex.com |
Stock Details
Ticker Symbol | CDXC |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001386570 |
CUSIP Number | 171077407 |
ISIN Number | US1710774076 |
Employer ID | 26-2940963 |
SIC Code | 2833 |
Key Executives
Name | Position |
---|---|
Robert N. Fried | Chief Executive Officer & Director |
Michiko Kelley | Chief Marketing Officer |
Ozan Pamir C.F.A. | Chief Financial Officer & Principal Accounting Officer |
Alex Worsham | Vice President of Global Marketing & Communications |
Carlos Lopez | Senior Vice President & General Counsel |
Chu Yan | Managing Director of Asia Pacific |
Dr. Andrew Shao Ph.D. | Senior Vice President of Global Regulatory & Scientific Affairs |
Frank Louis Jaksch Jr. | Co-Founder & Chairman |
James Lee | Controller |
Kendall Knysch | Head of Media Relations & Partnerships |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 04, 2024 | 8-K | Current Report |
Nov 25, 2024 | 4 | Filing |
Nov 21, 2024 | 424B3 | Filing |
Nov 21, 2024 | 8-K | Current Report |
Nov 08, 2024 | 3 | Filing |
Oct 31, 2024 | 8-K | Current Report |
Oct 31, 2024 | 10-Q | Quarterly Report |
Oct 23, 2024 | 4 | Filing |
Oct 23, 2024 | 3 | Filing |
Oct 11, 2024 | 8-K | Current Report |